- $513.89m
- $417.99m
- $85.23m
Brief: Delcath Systems Extends Term Of Agreement To December 31, 2028
Brief: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Inc reports results for the quarter ended in December - Earnings Summary
Delcath Systems Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Delcath Systems Announces $7 Mln Private Placement
Brief: Delcath Systems Receives Permanent J-Code (J9248) For Hepzato
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
Delcath Systems Inc expected to post a loss of 52 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
U.S. STOCKS ON THE MOVE-Arcellx, U.S. Steel, Copper miners
U.S. STOCKS ON THE MOVE-Getty Images, Tiziana, LL Flooring
U.S. STOCKS ON THE MOVE-SCYNEXIS, Paysafe, Big banks
U.S. STOCKS ON THE MOVE-Nvidia, Delcath, Alaunos Therapeutics
Delcath surges on FDA approval for cancer treatment
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte
Brief: Delcath Systems Announces FDA Approval Of HEPZATO KIT for The Treatment Of Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
Delcath Systems Inc reports results for the quarter ended in June - Earnings Summary
Brief: Delcath Systems Inc Said A Vendor Inadvertently Published Staging Site To Reflect Possibility That U.S. FDA Might Approve Hepzato